

# Correction: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, *EGFR*-Mutated Non-Small Cell Lung Cancer



In Table 1 in the original version of this article (1), the value in row “Ex19ins” and column “Pooled RDE” should be “1 (2).” Table 1 has been corrected in the latest online HTML and PDF versions of the article. The authors regret the error.

## REFERENCE

1. Jänne PA, Baik C, Su WC, Johnson ML, Hayashi H, Nishio M, et al. Efficacy and safety of patritumab derux-tecan (HER3-DXd) in EGFR inhibitor-resistant, *EGFR*-mutated non-small cell lung cancer. *Cancer Discov* 2022;12:74-89.

---

Published first June 2, 2022.

*Cancer Discov* 2022;12:1598

doi: 10.1158/2159-8290.CD-22-0365

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.

©2022 The Authors; Published by the American Association for Cancer Research